诺瓦瓦克斯医药（NVAX）股价在夜盘交易中大涨11.44%，引起投资者广泛关注。这一显著涨幅主要源于一则重要利好消息。
美国食品和药物管理局（FDA）批准了诺瓦瓦克斯的COVID-19疫苗Nuvaxovid，但仅限于特定人群使用。获准使用的对象包括65岁及以上的老年人，以及12至64岁之间至少患有一种可能增加COVID-19重症风险的潜在疾病的人群。这项批准被公司视为一个"重要的里程碑"，为更多人获得疫苗铺平了道路。
值得注意的是，这项批准来之不易。诺瓦瓦克斯公司首席企业事务与宣传官西尔维亚·泰勒表示，公司在与监管机构进行了大量来回沟通后，于上周五深夜收到了批准通知。此前，FDA曾多次推迟审批决定。尽管批准范围有限，但公司认为这符合目前寻求接种疫苗的人群特征。这一突破性进展极大地提振了投资者信心，推动了公司股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.